Hepatic steatosis in people older and younger than fifty who are living with HIV and HIV‐negative controls: A cross‐sectional study nested within the POPPY cohort

BACKGROUND Hepatic steatosis is a major cause of chronic liver disease associated with several negative health outcomes. We compared the prevalence of and factors associated with steatosis in people living with and without HIV. METHODS Older (>50 years) and younger (<50 years) people with HIV and older HIV-negative controls (>50 years) underwent liver transient elastography examination with controlled attenuation parameter (steatosis ≥238 dB/m, moderate/severe steatosis ≥280 dB/m, liver fibrosis ≥7.1 kPa). We compared groups using logistic regression/Chi-squared/Fisher's exact/Kruskal-Wallis tests. RESULTS In total, 317 participants (109 older people with HIV; 101 younger people with HIV; 107 HIV-negative controls) were predominantly white (86%) and male (76%), and 21% were living with obesity (body mass index ≥30 kg/m2 ). Most (97%) people with HIV had undetectable HIV RNA. The prevalence of fibrosis was 8.4%, 3.0%, and 6.5% in the three groups, respectively (p = 0.26). Fibrosis was predominately (>65%) mild. The prevalence of steatosis was the same in older people with HIV (66.4%) and controls (66.4%) but lower in younger people with HIV (37.4%; p < 0.001). After adjustment, younger people with HIV were less likely to have steatosis (odds ratio [OR] 0.26; 95% confidence interval [CI] 0.14-0.52) than controls, but male sex (OR 2.45; 95% CI 1.20-4.50) and high waist-to-hip ratio (OR 3.04; 95% CI 1.74-5.33) were associated with an increased odds of steatosis. We found no association between steatosis and HIV-related variables. CONCLUSIONS The prevalence of hepatic steatosis and fibrosis was similar between older participants regardless of HIV status. Age, sex, and abdominal obesity, but not HIV-related variables, were associated with steatosis. Interventions for controlling obesity should be integrated into routine HIV care.

[1]  Yang Zou,et al.  Abdominal obesity phenotypes are associated with the risk of developing non-alcoholic fatty liver disease: insights from the general population , 2022, BMC Gastroenterology.

[2]  Myeong Jun Song,et al.  Advancing the global public health agenda for NAFLD: a consensus statement , 2021, Nature Reviews Gastroenterology & Hepatology.

[3]  J. Rockstroh,et al.  Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART) , 2021, EClinicalMedicine.

[4]  J. Esplugues,et al.  NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved , 2021, Cells.

[5]  F. Bendtsen,et al.  Hepatic steatosis associated with exposure to elvitegravir and raltegravir. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  C. Sirlin,et al.  Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Zins,et al.  Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: the French Nationwide NASH-CO Study. , 2020, Gastroenterology.

[8]  A. Winston,et al.  Factors associated with obesity in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) cohort: an observational cross‐sectional analysis , 2020, HIV medicine.

[9]  J. Milic,et al.  Prevalence, predictors and severity of lean non-alcoholic fatty liver disease in HIV-infected patients. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  P. Bossuyt,et al.  Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. , 2020, Journal of hepatology.

[11]  G. Sebastiani,et al.  Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection , 2020, The Journal of Infectious Diseases.

[12]  Richard D Moore,et al.  Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada , 2020, Journal of the International AIDS Society.

[13]  F. Palella,et al.  Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  R. Loomba,et al.  Advances in non-invasive assessment of hepatic fibrosis , 2020, Gut.

[15]  H. Stellbrink,et al.  Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  C. Fìlice,et al.  Drug-induced liver steatosis in patients with HIV infection. , 2019, Pharmacological research.

[17]  K. Sherman,et al.  Fatty liver disease in persons with HIV infection. , 2019, Topics in antiviral medicine.

[18]  A. Winston,et al.  Cohort profile: The Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study. , 2018, International journal of epidemiology.

[19]  R. Hultcrantz,et al.  Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long‐term follow‐up study , 2017, Hepatology communications.

[20]  Michael T. Lu,et al.  Differential relationships of hepatic and epicardial fat to body composition in HIV , 2017, Physiological reports.

[21]  E. Verna,et al.  Managing nonalcoholic fatty liver disease in patients living with HIV , 2016, Current opinion in infectious diseases.

[22]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[23]  M. Budoff,et al.  Risk Factors for Fatty Liver in the Multicenter AIDS Cohort Study , 2014, The American Journal of Gastroenterology.

[24]  Korbinian Brand,et al.  The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. , 2013, Journal of hepatology.

[25]  C. Thio,et al.  HIV monoinfection is associated with increased aspartate aminotransferase-to-platelet ratio index, a surrogate marker for hepatic fibrosis. , 2012, The Journal of infectious diseases.

[26]  C. Torti,et al.  Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  H. Kim,et al.  Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[28]  N. Lundbom,et al.  Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. , 2009, Gastroenterology.

[29]  G. Ligabue,et al.  Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  Eric Schulte Nordholt Imputation: Methods, Simulation Experiments and Practical Examples , 1998 .

[31]  B. Fromenty,et al.  Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. , 2011, Journal of hepatology.